stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Gross margin
BioNTech SE Sponsored ADR's gross margin over the twelve months to 30 September 2026 was 74.6%, down 3.0 percentage points from fiscal 2025 (77.6%). Over the past ten years it has ranged from 68.1% (fiscal 2017) to 89.3% (fiscal 2018); the current reading is higher than 22% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 77.6% | (2.68) |
| FY2024 | 80.3% | (3.97) |
| FY2023 | 84.3% | 1.59 |
| FY2022 | 82.7% | (1.96) |
| FY2021 | 84.7% | (3.04) |
| FY2020 | 87.7% | 3.69 |
| FY2019 | 84.0% | (5.26) |
| FY2018 | 89.3% | 21.15 |
| FY2017 | 68.1% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 92.0% | 83.85 |
| Jun 2026 | 8.14% | (31.40) |
| Mar 2026 | 39.5% | (22.03) |
| Dec 2025 | 61.6% | (28.67) |
| 24 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| GMAB Genmab A/S Sponsored ADR compare | 93.0% |
| INCY Incyte Corporation compare | 92.7% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| INSM Insmed, Inc. compare | 84.4% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement